NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 17 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Details Board Additions, AI Partnerships and M&A Moves
Onar (OTCQB: ONAR), a marketing technology company and global network of performance-driven agencies, issued a…
-
QualityStocksNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sees 504% Boat Sales Surge, Slashes Debt Following Nautical Ventures Acquisition
Vision Marine Technologies (NASDAQ: VMAR), a leader in electric marine propulsion and multi-brand boat…
-
Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures $18.4M DoD Award to Fast-Track Heavy Rare Earth Independence
This phase 2 award builds on phase 1 success, during which Ucore successfully separated two heavy…